- Advertise
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Rapid Readouts
OncLive presents Rapid Readouts. In each video, leading experts in their field present slides and posters from annual oncology conferences, symposiums, and meetings, highlighting the everchanging landscape of treatment choices for patient management.
Phase 1/2 Study of Mobocertinib in mNSCLC With EGFR Exon 20 Insertions: EXCLAIM and Platinum-Pretreated Patients Cohorts
February 19th, 2021
Rapid Readouts: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up
July 8th, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial
October 15th, 2021
ARCHES Final OS Analysis in mHSPC
October 15th, 2021
Rapid Readouts: ODENZA trial
October 7th, 2021
Rapid Readouts: IKEMA Subgroup Analysis in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics
September 24th, 2021
Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer
September 9th, 2021
Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer
August 11th, 2021
Rapid Readouts: Results from the Phase 3 VISION Study
August 11th, 2021
Rapid Readouts: First interim analysis of the ALPINE study: a phase III randomized trial of zanubrutinib vs. ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
July 14th, 2021
Rapid Readouts: Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicentre, open-label phase 2 trial
July 14th, 2021
Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ARROW trial
July 13th, 2021
Rapid Readouts: Updated Results From the Phase 3 SIMPLIFY-1 Trial
July 8th, 2021
Rapid Readouts: SIMPLIFY-1 and SIMPLIFY-2 Trials
July 8th, 2021
Rapid Readouts: Final Analysis of Phase 3 TITAN Trial
July 6th, 2021
Rapid Readouts: Results of the SCOUT and NAVIGATE Trials
July 1st, 2021
Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer
July 1st, 2021
Rapid Readouts: Updated data from a pooled analysis of larotrectinib in TRK fusion-positive cancers
July 1st, 2021
Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial
June 30th, 2021
Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial
June 30th, 2021
Rapid Readouts: Final Results from Phase 3 ClarIDHy Trial
June 24th, 2021
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
June 18th, 2021
Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial
June 18th, 2021
Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres
May 12th, 2021
Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL
May 7th, 2021
Rapid Readouts: Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk MDS/CMML or LB AML
April 28th, 2021
Rapid Readouts: Phase 2 CodeBreak 100 Trial
March 4th, 2021
Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study
March 3rd, 2021
.png?w=300&fit=crop&auto=format)
Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA
February 19th, 2021
Rapid Readouts: Patient-Reported Outcomes from ADAURA
February 19th, 2021
Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL
January 28th, 2021
Rapid Readouts: Phase 2 JULIET Trial
January 26th, 2021
Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer
January 19th, 2021
Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study
January 18th, 2021
Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma
January 18th, 2021
Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis
January 15th, 2021
Rapid Readouts: Results from the Phase 3 ANDROMEDA Study
January 14th, 2021
Rapid Readouts: Five-Year Analysis of MURANO Study
December 23rd, 2020
Rapid Readouts: Updated Results From KX-ORAX-001 Study
December 23rd, 2020
Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study
December 23rd, 2020
Rapid Readouts: Updated Results From DESTINY-Breast01
December 23rd, 2020
.png?w=300&fit=crop&auto=format)
Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy
December 10th, 2020
.png?w=300&fit=crop&auto=format)
Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2
December 10th, 2020
Rapid Readouts: Phase 3 VIALE-A Study
December 3rd, 2020
Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial
November 18th, 2020
Rapids Readouts: Phase 3 CheckMate 238 Trial
October 30th, 2020
Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results
October 14th, 2020
Rapid Readouts: Phase 3 HERO Trial
October 8th, 2020
Rapid Readouts: Phase 3 CheckMate 9ER Trial
October 7th, 2020
Rapid Readouts: Phase 3 ASCENT Study
October 5th, 2020
Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial
August 24th, 2020
Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX
July 17th, 2020
Rapid Readouts: Initial Results of the Phase III BOSTON Study
June 29th, 2020
Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial
June 25th, 2020
Rapid Readouts: Three-Year Update From CheckMate 227, Part 1
June 23rd, 2020
Rapid Readouts: Final Analysis of KEYNOTE-189
June 23rd, 2020
Rapid Readouts: Update of CARTITUDE-1
June 23rd, 2020
Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma
June 19th, 2020
Rapid Readouts: CheckMate 9LA
June 16th, 2020
Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis
June 16th, 2020